Select the optimum dose of exicorilant plus enzalutamide for CRPC patients

Not delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 8 Feb 2021
Due: 30 Sep 2021
Checked: 25 Oct 2026

Deadline
Met
Late
Not met
Today

What the company said

“Selection of optimum dose of exicorilant plus enzalutamide in patients with castration-resistant prostate cancer (“CRPC”) expected by third quarter 2021”

SourceCorcept Therapeutics Inc. Form 8-K press release, 2021-02-08
FilingSEC filing index
Deadline as statedthird quarter 2021
Deadline used30 Sep 2021, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2021-CORT-023298
Cite as https://keptindex.org/c/KI-C-2021-CORT-023298/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company failed to select the optimum dose by the Q3 2021 deadline, subsequently pushing the expected date to later in 2021 and then to the second quarter of 2022.

A
Corcept Therapeutics Inc. 8-K filed 2021-11-03 Regulatory filing · published 3 Nov 2021 · retrieved 25 Oct 2026 · kept permanently by the SEC · fingerprint c9f9c5973f9a
“Selection of the optimum dose of exicorilant plus enzalutamide in patients with castration-resistant prostate cancer (CRPC) expected later this year” ✓ confirmed on the page
A
Corcept Therapeutics Inc. 8-K filed 2022-02-15 Regulatory filing · published 15 Feb 2022 · retrieved 25 Oct 2026 · kept permanently by the SEC · fingerprint 7de4dd16e637
“Selection of the optimum dose of exicorilant or relacorilant plus enzalutamide in patients with castration-resistant prostate cancer (CRPC) expected in second quarter 2022” ✓ confirmed on the page

Checked 25 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +92 days
2 versions

Version 1 · original · stated 8 Feb 2021

Deadline 30 Sep 2021 (“third quarter 2021”) · wording expected
Version 2 · stated 3 Nov 2021

Deadline 31 Dec 2021 (“later this year”) · wording expected

“Selection of the optimum dose of exicorilant plus enzalutamide in patients with castration-resistant prostate cancer (CRPC) expected later this year”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Product other
Indicative materiality: Low rules
Action: Select
Deliverable: Optimum dose selection
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Corcept Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.